Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study

Hidenori Hirukawa, Shinji Kamei, Tomohiko Kimura, Atsushi Obata, Kenji Kohara, Fuminori Tatsumi, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, and Hideaki Kaneto

Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan

Correspondence should be addressed to Hidenori Hirukawa; hirukawa@med.kawasaki-m.ac.jp

Received 11 April 2018; Revised 15 September 2018; Accepted 18 September 2018; Published 7 November 2018

1. Introduction

It is known that the augmentation of urinary albumin excretion (UAE) is associated with vascular endothelium disorder and is an independent risk factor for ischemic heart disease [1–5]. In addition, the increase of UAE leads to the ratio of cardiovascular disease-related mortality even before the onset of diabetic nephropathy [6, 7]. Therefore, it is very important to explore how we can reduce UAE. Hyperglycemia and subsequent activation of renin-angiotensin system (RAS) are associated with the development of diabetic nephropathy [8–12]. It was reported that RAS inhibitors suppressed the progression of overt diabetic nephropathy [13–16]. It remained unclear, however, whether RAS inhibitors exert such beneficial effects even before the onset of diabetic nephropathy. In this study, we retrospectively evaluated the effects of RAS inhibitor therapy on diabetic nephropathy in Japanese subjects whose urinary albumin levels were within normal range.

2. Methods

We enrolled the subjects with type 2 diabetes who visited Department of Diabetes, Endocrinology and Metabolism in Kawasaki Medical School and did not take any RAS inhibitor. We defined the subjects who started taking RAS inhibitor and continued for more than 3 years as RAS inhibitor group and the subjects who did not start any RAS inhibitor as control group. In RAS inhibitor group, 57 subjects had angiotensin II receptor blocker, 2
subjects had angiotensin-converting-enzyme inhibitor, and 1 subject had renin inhibitor. The study protocol was approved by our hospital ethics committee (no. 2419).

Clinical characteristics at baseline in RAS inhibitor group (n = 60, male/female = 35/25) and control group (n = 100, male/female = 60/40) were as follows: age, 60.0 ± 1.1 vs. 63.0 ± 1.4 years old (not significant (n.s.)); duration of diabetes, 11.3 ± 1.1 vs. 9.5 ± 1.1 years (n.s.); HbA1c, 7.09 ± 0.09% vs. 7.01 ± 0.13% (n.s.); Hb, 14.0 ± 0.2 g/dL vs. 13.6 ± 0.1 g/dL (n.s.); BMI, 23.8 ± 0.4 kg/m² vs. 26.3 ± 0.8 kg/m² (p < 0.05); LDL cholesterol, 103.2 ± 2.7 mg/dL vs. 104.4 ± 3.5 mg/dL (n.s.); HDL cholesterol, 54.0 ± 1.6 mg/dL vs. 55.1 ± 2.5 mg/dL (n.s.); triglyceride, 131.9 ± 9.3 mg/dL vs. 127.6 ± 10.8 mg/dL (n.s.); systolic blood pressure, 122.1 ± 1.8 mmHg vs. 130.3 ± 2.0 mmHg (p < 0.05); diastolic blood pressure, 70.6 ± 1.3 mmHg vs. 72.8 ± 1.6 mmHg (n.s.); urinary albumin excretion (UAE), 13.3 ± 0.6 mg/gCr vs. 13.6 ± 0.9 mg/gCr (n.s.); eGFR, 83.8 ± 2.3 mL/min/1.73m² vs. 79.4 ± 2.3 mL/min/1.73m²; uric acid, 5.6 ± 0.2 mg/dL vs. 5.3 ± 0.1 mg/dL (n.s.); prevalence of diabetic retinopathy, 14.3% vs. 9.3% (n.s.); smoking status, 40.8% vs. 44.4% (n.s.); and family history of diabetes, 55.6% vs. 58.1% (n.s.). There was no difference in the ratio of antidiabetic drug use between the 2 groups. Similarly, there was no difference in the ratio of lipid-lowering drug use between the 2 groups: statin, 45.0% vs. 46.0% (RAS inhibitor group vs. control group) (n.s); fibrates, 8.3% vs. 6.0% (n.s.); and ezetimibe, 55.6% vs. 58.1% (n.s.).

An analysis of the relative odds of the occurrence of the outcome was performed with the use of a logistic regression model.

3. Results

There was no difference in HbA1c levels between RAS inhibitor group and control group through the 3-year observation period (Figure 1(a)). Systolic blood pressure in RAS inhibitor group was higher compared to that in control group at baseline and 1 year after starting RAS inhibitor (p < 0.05), but there was no difference between them 2 and 3 years after the treatment. There was no difference in diastolic blood pressure between the 2 groups. BMI in RAS inhibitor group was higher compared to that in control group through the observation period (p < 0.05).

Urinary albumin excretion (UAE) in control group was significantly increased compared to baseline (from 13.5 ± 0.5 mg/gCr to 26.2 ± 2.2 mg/gCr) (p < 0.05), whereas there was no significant difference in RAS inhibitor group between at
baseline and 3 years after the treatment (13.6 ± 0.6 mg/gCr and 19.6 ± 2.7 mg/gCr) (Figure 1(b)). The alteration of UAE in RAS inhibitor group and control group was 2.5 ± 1.6 mg/gCr and 11.4 ± 2.2 mg/gCr, respectively. In addition, 2 and 3 years after the treatment, there was significant difference in UAE between the 2 groups (p < 0.05). UAE in 33% of control group increased up to ≥30 mg/gCr whereas only 15% of RAS inhibitor group increased up to ≥30 mg/gCr (Figure 1(c)). These data suggest that RAS inhibitor therapy exerts protective effect on the progression of UAE.

Next, we evaluated odds ratio about the progression of diabetic nephropathy. As shown in Figure 2, odds ratio (95% CI) for favorable effect of RAS inhibitor on urinary albumin excretion. Comparison of odds ratio between the subjects with HbA1c <7.0% and ≥7.0% and between the subjects with blood pressure <130/80 mmHg and ≥130/80 mmHg.

Table 1: Association between the alteration of urinary albumin excretion and various clinical parameters: univariate analysis.

|                | Control group | RAS inhibitor group |
|----------------|---------------|---------------------|
| β              | p             | r                   | p       |
| HbA1c, annual mean | 7.574         | <0.0005             | -1.749  | n.s. |
| Age, baseline   | 0.208         | n.s.                | 0.171   | n.s. |
| Systolic BP, annual mean | -0.021 | n.s.                | 0.165   | n.s. |
| Gender          | 0.533         | n.s.                | 1.017   | n.s. |
| eGFR, baseline  | 0.019         | n.s.                | 0.142   | n.s. |

Abbreviations: n.s., not significant; BP, blood pressure; RAS, renin-angiotensin system.

Table 2: Association between the alteration of urinary albumin excretion and various clinical parameters: multivariate analysis.

|                | β              | p       | R                   | p       |
|----------------|----------------|---------|---------------------|---------|
| HbA1c, annual mean | 7.574         | <0.0005 | -1.749              | n.s.    |
| Age, baseline   | 0.208         | n.s.    | 0.171               | n.s.    |
| Systolic BP, annual mean | -0.021 | n.s.    | 0.165               | n.s.    |
| Gender          | 0.533         | n.s.    | 1.017               | n.s.    |
| eGFR, baseline  | 0.019         | n.s.    | 0.142               | n.s.    |

Abbreviations: n.s., not significant; BP, blood pressure; RAS, renin-angiotensin system.

Furthermore, to adjust the possible influence of blood pressure, eGFR, age, and gender on the alteration of UAE, we performed multivariate analysis using annual mean of HbA1c levels, systolic blood pressure, GFR and age at baseline, and gender as explanatory variables and the alteration of UAE as an objective variable. As shown in Table 2, annual mean of HbA1c levels was an independent determinant factor for the alteration of UAE in control group (β = 7.574, p < 0.005), but not in RAS inhibitor group (β = -1.749, p: n.s.). These data strengthened the idea that RAS inhibitor could protect renal function against the deleterious effect of chronic hyperglycemia in subjects with type 2 diabetes without diabetic nephropathy.

4. Discussion

It was known that RAS inhibitors suppressed the progression of overt diabetic nephropathy, but it remained unclear whether RAS inhibitors would bring out some favorable effects on renal function even before the onset of diabetic nephropathy. In this study, we showed that RAS inhibitor
could exert protective effect on the progression of UAE and could counteract the adverse effect of hyperglycemia in subjects with type 2 diabetes even before the onset of diabetic nephropathy (Figure 1). RAS inhibitor exerted more protective effects on renal function in subjects with poor glycemic control (Figure 2). Therefore, it is likely that administration of RAS inhibitor reduces the adverse effect of hyperglycemia on the progression of UAE. In addition, these data suggest that it is more important to use RAS inhibitor when glycemic control is poor. Poor glycemic control was an independent determinant factor for the alteration of UAE in control group, but such findings were not observed in RAS inhibitor group (Table 2). These data suggest that deleterious effect of chronic hyperglycemia on renal function was reduced by the usage of RAS inhibitor in subjects with type 2 diabetes before the onset of diabetic nephropathy. In addition, RAS inhibitor exerted more protective effects on renal function in subjects with good control of blood pressure (Figure 2). These data suggest that it is very important to maintain good control of blood pressure so that RAS inhibitor could bring out more favorable effect on the progression of UAE and protection of renal function. Taken together, it is likely that RAS inhibitor exerts more beneficial effects in subjects with poor glycemic control and good control of blood pressure.

There are several limitations in this study. First, this is a retrospective study, but not a prospective study. Therefore, it would be necessary to perform a prospective study with a placebo control in order to strengthen our hypothesis. Second, the data in this study are influenced by lifestyle, diet, and other factors such as alternative medicine. Therefore, it would be necessary to perform some intervention to various factors including lifestyle so that we can demonstrate our hypothesis.

In conclusion, RAS inhibitor could protect renal function against the deleterious effect of chronic hyperglycemia in Japanese subjects with type 2 diabetes even before the onset of diabetic nephropathy.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

Hideaki Kaneto has received honoraria for lectures and received scholarship grants from Sanofi, Novo Nordisk, Lilly, Boehringer Ingelheim, MSD, Takeda, Ono Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Pfizer, Kissei Pharma, AstraZeneca, Astellas, Novartis, Kowa, Chugai, and Taisho Pharma. Kohei Kaku has been an advisor to, received honoraria for lectures from, and received scholarship grants from Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Takeda, Taisho Pharmaceutical Co. Ltd, MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe Pharma, AstraZeneca, Nippon Boehringer Ingelheim Co. Ltd, Chugai, Daiichi Sankyo, and Sanofi.

Funding

This work was supported by a Grant-in-Aid from the Japan Society for the Promotion of Science (no. 16K09770 to H. K.) and Research Project Grants from the Kawasaki Medical School (no. 28-021 to H. K.).

References

[1] H. Ibsen, M. H. Olsen, K. Wachtell et al., “Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study,” Diabetes Care, vol. 29, no. 3, pp. 595–600, 2006.
[2] P. Gæde, P. Vedel, N. Larsen, G. V. H. Jensen, H.-H. Parving, and O. Pedersen, “Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes,” New England Journal of Medicine, vol. 348, no. 5, pp. 383–393, 2003.
[3] M. Afkarian, M. C. Sachs, B. Kestenbaum et al., “Kidney disease and increased mortality risk in type 2 diabetes,” Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 302–308, 2013.
[4] H. B. Al-Saffar, H. Nassir, A. Mitchell, and S. Philipp, “Micro-albuminuria in non-diabetic patients with unstable angina/ non ST-segment elevation myocardial infarction,” BMC Research Notes, vol. 8, no. 1, p. 371, 2015.
[5] H. Ota, N. Takehara, T. Aonuma et al., “Association between microalbuminuria predicting in-stent restenosis after myocardial infarction and cellular senescence of endothelial progenitor cells,” PLoS One, vol. 10, no. 4, article e012373, 2015.
[6] H. C. Gerstein, J. F. Mann, Q. Yi et al., “Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals,” JAMA, vol. 286, no. 4, pp. 421–426, 2001.
[7] F. Persson, M. Lindhardt, P. Rossing, and H.-H. Parving, “Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 17, no. 3, 2016.
[8] UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998.
[9] B. M. Brenner, M. E. Cooper, D. de Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001.
[10] E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., “Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,” New England Journal of Medicine, vol. 345, no. 12, pp. 851–860, 2001.
[11] S. Nakatani, E. Ishimura, T. Nagamura et al., “Poor glycemic control and decreased renal function are associated with increased intrarenal RAS activity in type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 105, no. 1, pp. 40–46, 2014.
[12] J. Gu, M. Yang, N. Qi et al., “Olmesartan prevents microalbuminuria in db/db diabetic mice through inhibition of angiotensin II/p38/SIRT1-induced podocyte apoptosis,” Kidney & Blood Pressure Research, vol. 41, no. 6, pp. 848–864, 2016.
[13] Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, "Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy," *The Lancet*, vol. 355, no. 9200, pp. 253–259, 2000.

[14] M. Haneda, R. Kikkawa, H. Sakai, R. Kawamori, and Candesartan in Diabetic Nephropathy Study Group, "Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy," *Diabetes Research and Clinical Practice*, vol. 66, no. 1, pp. 87–95, 2004.

[15] M. Urushihara and S. Kagami, "Role of the intrarenal renin-angiotensin system in the progression of renal disease," *Pediatric Nephrology*, vol. 32, no. 9, pp. 1471–1479, 2017.

[16] J. Paeng, J. Park, J. E. Um et al., "The locally activated renin-angiotensin system is involved in albumin permeability in glomerular endothelial cells under high glucose conditions," *Nephrology, Dialysis, Transplantation*, vol. 32, pp. 61–72, 2017.